Get the Stockscreener App
6.19
0.65%
0.04
Cns Pharmaceuticals Inc stock is traded at $6.19, with a volume of 9,674.
It is up +0.65% in the last 24 hours and down -18.98% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$6.15
Open:
$6.18
24h Volume:
9,674
Relative Volume:
0.25
Market Cap:
$3.56M
Revenue:
-
Net Income/Loss:
$-17.06M
P/E Ratio:
-0.0875
EPS:
-70.7173
Net Cash Flow:
$-14.18M
1W Performance:
-0.16%
1M Performance:
-18.98%
6M Performance:
-79.20%
1Y Performance:
-93.12%
1-Day Range:
$5.88
$6.315
1-Week Range:
$5.88
$6.37
52-Week Range:
$4.93
$221.94
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
6.19 | 3.53M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Sentiment analysis tools applied to CNS Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
Momentum divergence signals in CNS Pharmaceuticals Inc. chartQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - Newser
What MACD signals say about CNS Pharmaceuticals Inc.2025 Momentum Check & Weekly Sector Rotation Insights - Newser
What is CNS Pharmaceuticals Inc. s P E ratio telling usJuly 2025 Snapshot & Safe Entry Trade Reports - خودرو بانک
Published on: 2025-09-05 22:58:42 - خودرو بانک
How moving averages guide CNS Pharmaceuticals Inc. tradingRate Cut & Fast Gain Swing Trade Alerts - Newser
Will CNS Pharmaceuticals Inc. benefit from macro trendsEntry Point & Daily Technical Forecast Reports - Newser
Does CNS Pharmaceuticals Inc. qualify in momentum factor screening2025 Fundamental Recap & Reliable Intraday Trade Alerts - Newser
Can CNS Pharmaceuticals Inc. grow without external fundingEarnings Risk Report & Risk Managed Trade Strategies - خودرو بانک
Can trapped investors hope for a rebound in CNS Pharmaceuticals Inc.Portfolio Return Report & Weekly High Momentum Picks - Newser
Visualizing CNS Pharmaceuticals Inc. stock with heatmapsFed Meeting & AI Powered Buy and Sell Recommendations - Newser
Harmony Biosciences: Pioneering Growth in the CNS Therapeutics Market Amid Strategic Advancements - AInvest
Detecting price anomalies in CNS Pharmaceuticals Inc. with AIPortfolio Gains Report & Consistent Income Trade Ideas - Newser
Does CNS Pharmaceuticals Inc. fit your quant trading modelQuarterly Market Summary & Verified Chart Pattern Signals - Newser
Can CNS Pharmaceuticals Inc. deliver alpha2025 Growth vs Value & Accurate Buy Signal Notifications - خودرو بانک
CNS Pharmaceuticals Inc. stock chart pattern explainedCPI Data & Advanced Technical Analysis Signals - Newser
Why CNS Pharmaceuticals Inc. is moving todayMarket Performance Summary & Fast Entry Momentum Alerts - Newser
What candlestick patterns are forming on CNS Pharmaceuticals Inc.CEO Change & Reliable Price Action Trade Plans - Newser
Applying sector rotation models to CNS Pharmaceuticals Inc.July 2025 Closing Moves & Technical Pattern Recognition Alerts - Newser
Real time breakdown of CNS Pharmaceuticals Inc. stock performanceWeekly Market Report & Safe Entry Trade Signal Reports - Newser
Can technical indicators confirm CNS Pharmaceuticals Inc.’s reversalJuly 2025 Decliners & Stepwise Swing Trade Plans - Newser
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference - 富途牛牛
Statistical indicators supporting CNS Pharmaceuticals Inc.’s strengthPortfolio Update Summary & Target Return Focused Stock Picks - Newser
CNS Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Market Mood & AI Forecasted Stock Moves - Newser
Price action breakdown for CNS Pharmaceuticals Inc.July 2025 Breakouts & Daily Technical Stock Forecast Reports - Newser
Will CNS Pharmaceuticals Inc. continue its uptrendWall Street Watch & Accurate Entry/Exit Alerts - Newser
Using flow based indicators on CNS Pharmaceuticals Inc.Trade Ideas & Daily Stock Momentum Reports - Newser
Visual analytics tools that track CNS Pharmaceuticals Inc. performance2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
How institutional ownership impacts CNS Pharmaceuticals Inc. stock2025 Technical Overview & Risk Controlled Swing Trade Alerts - Newser
Short Squeeze: Will CNS Pharmaceuticals Inc. outperform during market ralliesShare Buyback & Smart Allocation Stock Tips - خودرو بانک
Is CNS Pharmaceuticals Inc.’s ROE strong enough2025 Market Overview & Community Trade Idea Sharing - خودرو بانک
Will CNS Pharmaceuticals Inc. outperform the market in YEARStock Surge & Short-Term Trading Alerts - خودرو بانک
Is CNS Pharmaceuticals Inc. forming a bullish divergenceJuly 2025 Setups & Daily Market Momentum Tracking - خودرو بانک
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):